Hearing Loss in Adults

1. Clinical Overview

Summary

Hearing loss is one of the most prevalent chronic conditions affecting adults worldwide, with profound implications for quality of life, cognitive function, and social participation. Approximately 1.5 billion people globally experience some degree of hearing impairment, with prevalence increasing sharply with age. [1,2]

Clinically, adult hearing loss is classified into three fundamental types:

1. Conductive Hearing Loss (CHL): Pathology affecting the external or middle ear that impairs sound transmission to the cochlea
2. Sensorineural Hearing Loss (SNHL): Dysfunction of the cochlea or auditory nerve pathway
3. Mixed Hearing Loss: Combination of conductive and sensorineural components

Presbycusis (age-related hearing loss) represents the most common form of SNHL, affecting more than 40% of adults over 50 years and 70% over 70 years. [6] It is characterized by bilateral, progressive, high-frequency hearing loss that significantly impacts speech discrimination, particularly in noisy environments.

Sudden Sensorineural Hearing Loss (SSNHL) is an otological emergency defined as ≥30 dB hearing loss across three contiguous frequencies occurring within 72 hours. [11] It affects 5-20 per 100,000 individuals annually and requires urgent corticosteroid therapy, as prognosis is time-dependent.

Recent epidemiological evidence has established untreated hearing loss as the single largest modifiable risk factor for dementia, accounting for approximately 8% of dementia cases. [2] This association underscores the critical importance of early identification and intervention.

Key Facts

Conductive vs Sensorineural Differentiation:

• CHL: Mechanical impedance to sound transmission. Volume is reduced but clarity preserved if amplification provided. Bone conduction (BC) superior to air conduction (AC) on audiometry.
• SNHL: Both volume and clarity affected due to hair cell dysfunction. Patients report "I can hear people talking but can't understand the words." Air conduction equivalent to bone conduction, both reduced.
• Mixed: Features of both components present.

Epidemiological Patterns:

• Prevalence doubles with each decade of life after age 50
• Men experience earlier onset and more severe presbycusis than women
• Occupational noise exposure affects 16% of disabling hearing loss in adults
• Sudden SNHL incidence: 5-20 per 100,000 annually [11,12]

Pathophysiological Mechanisms:

• Presbycusis: Cumulative loss of cochlear hair cells, particularly at the basal turn (high frequencies), compounded by strial atrophy and neural degeneration [6,8]
• Otosclerosis: Abnormal bone remodeling causing stapes fixation, most common in young women (F:M ratio 2:1)
• Noise-induced: Permanent threshold shift from acoustic trauma, characteristically affecting 4 kHz (ear canal resonance frequency)

Cognitive-Auditory Link:

• Hearing loss reduces auditory input to temporal cortex, accelerating cortical atrophy
• Increased cognitive load from effortful listening depletes executive function reserves
• Social isolation from communication difficulty compounds cognitive decline [2,4]

Clinical Pearls

The "Hum Test" (Occlusion Effect)

Ask the patient to hum while occluding each ear alternately.

• If louder in affected ear → Conductive loss (occlusion traps bone-conducted sound)
• If louder in normal ear → Sensorineural loss

This bedside test confirms Weber test findings and helps patients understand their loss pattern.

Sudden Hearing Loss Protocol

"I woke up deaf in one ear" = SSNHL until proven otherwise

• DO NOT assume wax without otoscopy confirmation
• If canal clear → immediate same-day ENT referral
• Oral prednisolone 1 mg/kg (max 60 mg) started within 72 hours improves outcomes
• Every day of delay reduces recovery probability [11,21]

Noise Notch Sign

Noise-induced hearing loss produces a characteristic "notch" on pure tone audiometry at 4 kHz

• Reflects ear canal resonance frequency maximizing acoustic energy at tympanic membrane
• High frequencies (6-8 kHz) may partially recover, creating the notch appearance
• Strongly suggestive of occupational or recreational noise exposure history

Unilateral SNHL Red Flag

Presbycusis is inherently bilateral and symmetrical

• Unilateral or asymmetric SNHL (greater than 15 dB difference at 2+ frequencies) mandates MRI internal acoustic meatus (IAM) to exclude vestibular schwannoma
• Approximately 3% of asymmetric SNHL cases harbor acoustic neuroma [12]

---

2. Epidemiology

Global Burden

Hearing loss represents the third most common chronic condition in older adults after arthritis and hypertension, affecting an estimated 1.5 billion people worldwide as of 2023. [1,2]

Prevalence by Age:

• 18-44 years: 4-6%
• 45-54 years: 12-15%
• 55-64 years: 25-30%
• 65-74 years: 40-45%
• ≥75 years: 60-75%

The exponential increase with age reflects cumulative exposure to genetic, environmental, and intrinsic aging factors.

Geographic and Demographic Variation

United Kingdom:

• 11 million adults (1 in 6) with hearing loss
• 6.7 million could benefit from hearing aids; only 2 million use them
• Annual cost to economy: £30 billion (lost productivity, healthcare, social care)

United States:

• 37.5 million adults (15%) report some degree of hearing loss
• Only 16% of adults aged 20-69 with hearing loss use hearing aids
• Disparities exist by race (higher in non-Hispanic whites) and socioeconomic status [2]

Australia and New Zealand:

• 3.6 million Australians affected
• 1 in 3 adults greater than 50 years
• Indigenous populations experience higher prevalence and earlier onset

Etiology Distribution

Conductive Hearing Loss Causes:

• Cerumen impaction: 2-6% of general population, 30% of geriatric population
• Otosclerosis: Prevalence 0.3-0.4%; clinical disease 0.2-1%; F:M ratio 2:1
• Chronic otitis media: 65-330 million globally with chronic suppurative otitis media
• Cholesteatoma: Incidence 3-12 per 100,000 adults annually

Sensorineural Hearing Loss Causes:

• Presbycusis: 40% of adults greater than 50, 70% greater than 70 [6]
• Noise-induced: 16% of adult hearing loss attributable to occupational noise
• Sudden SNHL: 5-20 per 100,000 annually [11]
• Meniere's disease: 190 per 100,000 prevalence
• Vestibular schwannoma: 1-2 per 100,000 annually
• Ototoxicity: Aminoglycosides (10-20% develop hearing loss), cisplatin (40-80% dose-dependent)

Risk Factors

Non-Modifiable:

• Advancing age (strongest predictor)
• Male sex (earlier onset, more severe presbycusis)
• Genetic predisposition (greater than 150 genes implicated in non-syndromic hearing loss)
• Race/ethnicity (higher in white populations)

Modifiable:

• Noise exposure: Occupational (construction, manufacturing, military), recreational (concerts, personal audio devices greater than 85 dB)
• Ototoxic medications: Aminoglycosides, loop diuretics, platinum chemotherapy, salicylates
• Cardiovascular risk factors: Hypertension, diabetes, dyslipidemia, smoking (all associated with accelerated presbycusis) [6,10]
• Low socioeconomic status: Associated with earlier onset and more severe hearing loss

Temporal Trends

Increasing Burden:

• Aging global population → rising prevalence
• Increased survival of ototoxic medication recipients (chemotherapy, neonatal intensive care)
• Recreational noise exposure in younger cohorts ("Generation Deaf")

Improving Outcomes:

• Advanced hearing aid and cochlear implant technology
• Earlier identification through screening programs
• Growing awareness of hearing loss-dementia link driving intervention

---

3. Pathophysiology

Normal Auditory Pathway

Sound transmission requires intact function across:

1. External ear: Pinna collects sound; external auditory canal conducts to tympanic membrane
2. Middle ear: Tympanic membrane vibration → malleus → incus → stapes → oval window (impedance matching 22:1 ratio)
3. Inner ear: Scala vestibuli fluid displacement → basilar membrane movement → hair cell deflection → neurotransmitter release
4. Auditory nerve: Spiral ganglion neurons → cochlear nerve → brainstem → auditory cortex

Conductive Hearing Loss Mechanisms

Pathophysiology: Obstruction or dysfunction anywhere from external canal to oval window prevents efficient sound energy transmission to cochlea. Bone conduction remains intact as it bypasses middle ear, creating air-bone gap on audiometry.

Common Mechanisms:

1. Cerumen Impaction

   • Complete canal occlusion required for significant hearing loss (≥25 dB)
   • Conductive component only; bone conduction normal

2. Tympanic Membrane Perforation

   • Degree of loss proportional to perforation size and location
   • Central perforations: typically 10-30 dB loss
   • Loss greater at low frequencies (longer wavelengths escape through perforation)

3. Otosclerosis

   • Abnormal bone remodeling at oval window → stapes footplate fixation
   • Autosomal dominant with incomplete penetrance
   • Carhart notch: Apparent bone conduction dip at 2 kHz (artifact of stapes fixation, not true cochlear loss)
   • Progressive; pregnancy often accelerates (estrogen effect on bone remodeling) [20]

4. Ossicular Chain Disruption

   • Trauma, chronic otitis media, cholesteatoma
   • Maximal loss ~60 dB (residual bone conduction preserves some hearing)

5. Cholesteatoma

   • Keratinizing squamous epithelium in middle ear
   • Erosive destruction of ossicles, mastoid, tegmen
   • "Unsafe ear" due to intracranial complication risk

Sensorineural Hearing Loss Mechanisms

Cochlear (Inner Ear) Pathology:

1. Presbycusis (Age-Related Hearing Loss)

   Multiple pathophysiological mechanisms interact: [6,8,10]

   • Sensory presbycusis: Outer hair cell loss, predominantly at basal turn (high frequencies)
   • Strial presbycusis: Atrophy of stria vascularis → reduced endocochlear potential → impaired hair cell function
   • Neural presbycusis: Spiral ganglion neuron degeneration
   • Mechanical presbycusis: Basilar membrane stiffness changes

   Molecular pathways:

   • Oxidative stress accumulation (mitochondrial DNA damage)
   • Inflammation (cochlear inflammaging)
   • Reduced cochlear blood flow (microvascular disease)
   • Genetic susceptibility (KCNQ4, CDH23, GRM7 variants) [9,10]

2. Noise-Induced Hearing Loss

   Acute acoustic trauma:

   • Mechanical shearing of stereocilia
   • Metabolic exhaustion of hair cells
   • Glutamate excitotoxicity at ribbon synapses

   Chronic noise exposure:

   • Cumulative oxidative stress
   • Chronic inflammation
   • Progressive outer hair cell loss
   • Hidden hearing loss: Selective cochlear synaptopathy (lost synapses but preserved hair cells) → difficulty in noise despite normal audiogram

3. Sudden Sensorineural Hearing Loss

   Etiology remains idiopathic in 70-90% of cases. Proposed mechanisms: [11,12,25]

   • Viral infection: Reactivation of latent viruses (HSV, VZV, CMV) in cochlea
   • Vascular occlusion: Microthrombosis or vasospasm of labyrinthine artery (end-artery with no collaterals)
   • Immune-mediated: Autoantibodies against inner ear antigens
   • Intracochlear membrane rupture: Perilymph fistula

   Corticosteroid mechanism of action:

   • Reduces cochlear inflammation
   • Stabilizes blood-labyrinth barrier
   • Improves microcirculation
   • Suppresses autoimmune response [21,24]

4. Ototoxicity

   Aminoglycosides (gentamicin, tobramycin, amikacin):

   • Preferentially damage outer hair cells at basal turn
   • Uptake via mechanotransduction channels → mitochondrial dysfunction → apoptosis
   • Bilateral, symmetrical, irreversible
   • Risk factors: Cumulative dose, renal impairment, concurrent loop diuretics

   Platinum chemotherapy (cisplatin, carboplatin):

   • DNA damage and oxidative stress in hair cells
   • Dose-dependent: 40-80% of patients receiving cisplatin greater than 300 mg/m²
   • Affects high frequencies first, progresses to speech frequencies

   Loop diuretics (furosemide):

   • Temporary reduction in endocochlear potential via strial dysfunction
   • Usually reversible unless combined with aminoglycosides (synergistic toxicity)

Retrocochlear (Neural) Pathology:

1. Vestibular Schwannoma (Acoustic Neuroma)

   • Benign tumor of Schwann cells on vestibular nerve (CN VIII)
   • Compression of cochlear nerve → progressive unilateral SNHL
   • Auditory brainstem response (ABR) shows prolonged wave V latency
   • MRI with gadolinium: gold standard diagnostic

2. Auditory Neuropathy Spectrum Disorder

   • Preserved cochlear hair cell function (otoacoustic emissions present)
   • Impaired neural synchrony (abnormal ABR)
   • Disproportionate difficulty with speech discrimination

Mixed Hearing Loss

Combination of conductive and sensorineural components. Common scenarios:

• Presbycusis + otosclerosis in elderly female
• Chronic otitis media + noise exposure in industrial worker
• Otosclerosis with cochlear involvement ("cochlear otospongiosis")

Audiometry shows air-bone gap (conductive component) with bone conduction thresholds below normal (sensorineural component).

---

4. Clinical Presentation

Symptomatology

Gradual-Onset Hearing Loss:

Patients rarely present with "hearing loss" as chief complaint. More commonly report:

• "People are mumbling or speaking unclearly" (especially in presbycusis - loss of consonant discrimination)
• "I can hear but can't understand" (classic SNHL description)
• Difficulty in noisy environments ("cocktail party effect"
• impaired signal-to-noise ratio processing)
• Frequent requests for repetition
• Television/radio volume complaints from family
• Social withdrawal (avoidance of group conversations, restaurants, social gatherings)

Frequency-Specific Patterns:

High-frequency loss (presbycusis, noise-induced):

• Consonants (f, s, t, th, sh) are high-frequency sounds
• Vowels (a, e, i, o, u) are low-frequency sounds
• Patients hear vowels (preserved volume) but miss consonants (lost clarity)
• Example: "fish" sounds like "ish," "sit" sounds like "it"

Low-frequency loss (Meniere's, otosclerosis):

• Fuller, "blocked ear" sensation
• More noticeable volume reduction
• Relatively preserved speech discrimination

Sudden-Onset Hearing Loss:

Sudden Sensorineural Hearing Loss (SSNHL):

• Abrupt onset over less than 72 hours, often overnight ("woke up deaf in one ear")
• Unilateral in 95% of cases
• Commonly associated symptoms:
  • Tinnitus (70-80% of SSNHL cases)
  • Aural fullness (40-50%)
  • Vertigo (30-40%; worse prognosis if present)
• Auditory hallucination ("popping" or "clicking" at onset) [11,12]

Sudden Conductive Loss:

• Cerumen impaction (often after ear irrigation attempt)
• Traumatic ossicular discontinuity
• Acute otitis media with effusion
• Barotrauma with hemotympanum

Associated Symptoms

Tinnitus:

• Accompanies 70-90% of sensorineural hearing loss
• Pathophysiology: Reduced peripheral auditory input → increased central gain → spontaneous neural activity perceived as sound
• Character correlates with hearing loss pattern (high-frequency loss → high-pitched tinnitus)

Vertigo and Imbalance:

• Suggests labyrinthine pathology (Meniere's, labyrinthitis, vestibular schwannoma)
• Presbycusis may include vestibular degeneration → imbalance, falls risk [10]

Otalgia:

• Uncommon in isolated hearing loss
• If present, consider:
  • Acute otitis media/externa
  • Malignancy (especially unilateral otalgia + hearing loss in greater than 50 years, smoker)
  • Cholesteatoma

Otorrhoea:

• Chronic otitis media (mucoid discharge)
• Cholesteatoma (foul-smelling, scanty discharge) - "unsafe ear" requiring urgent ENT referral
• Otitis externa (purulent, painful)

Red Flag Features

Clinical scenarios requiring urgent investigation or specialist referral:

1. Sudden sensorineural hearing loss - Same-day ENT assessment, oral corticosteroids
2. Unilateral or asymmetric SNHL - MRI IAM to exclude vestibular schwannoma
3. Progressive unilateral hearing loss + tinnitus - Vestibular schwannoma until proven otherwise
4. Hearing loss + persistent unilateral otorrhoea (especially foul-smelling) - Cholesteatoma
5. Hearing loss + facial nerve palsy - Malignancy (temporal bone), cholesteatoma, Ramsay Hunt syndrome
6. Hearing loss + headache/neurological signs - Intracranial pathology
7. Pulsatile tinnitus + hearing loss - Vascular anomaly (glomus tumor, arteriovenous malformation, sigmoid sinus dehiscence)
8. Otalgia + hearing loss in greater than 50-year-old smoker - Nasopharyngeal or temporal bone malignancy

Psychosocial Impact

Hearing loss profoundly affects quality of life across multiple domains:

Communication and Social:

• Social isolation and loneliness
• Relationship strain (frustration from communication partners)
• Reduced participation in social activities
• Occupational limitations

Cognitive and Mental Health:

• Dementia risk: Mild hearing loss (HR 1.9), moderate (HR 3.0), severe (HR 5.0) [2]
• Depression and anxiety
• Cognitive load from effortful listening
• Reduced processing speed and executive function [4]

Safety:

• Increased falls risk (vestibular co-involvement, reduced spatial awareness)
• Reduced awareness of environmental hazards (traffic, alarms)

Quality of Life:

• Hearing Handicap Inventory for Adults (HHIA) quantifies subjective impact
• SF-36 scores reduced across all domains in untreated hearing loss

---

5. Clinical Examination

History-Taking

Symptom Characterization:

• Onset: Sudden (less than 72 hours) vs gradual (months-years)
• Laterality: Unilateral, bilateral, asymmetric
• Progression: Stable, progressive, fluctuating
• Frequency pattern: High-frequency (consonant loss), low-frequency (vowel loss), flat

Associated Symptoms:

• Tinnitus (character, pitch, pulsatile/non-pulsatile)
• Vertigo or imbalance
• Otalgia, otorrhoea, aural fullness
• Facial weakness or numbness

Risk Factor Assessment:

• Noise exposure: Occupational (cumulative years greater than 85 dB), recreational (concerts, firearms, personal audio greater than 80% volume)
• Ototoxic medications: Current/previous aminoglycosides, chemotherapy, loop diuretics, high-dose aspirin
• Cardiovascular risk factors: Hypertension, diabetes, smoking, dyslipidemia
• Family history: Otosclerosis, early-onset hearing loss
• Temporal bone trauma: Head injury, barotrauma
• Autoimmune disease: Systemic lupus erythematosus, granulomatosis with polyangiitis

Functional Impact:

• Hearing Handicap Inventory screening questions
• Occupational impact
• Social withdrawal
• Hearing aid use and satisfaction

Otoscopic Examination

External Auditory Canal:

• Cerumen: Degree of occlusion (complete occlusion required for significant CHL)
• Otitis externa: Erythema, edema, discharge, pain on tragal pressure
• Foreign body
• Exostoses/osteomas: Benign bony growths (common in cold-water swimmers)
• Malignancy: Ulceration, bleeding, mass (rare)

Tympanic Membrane:

Normal appearance:

• Pearly grey, translucent
• Light reflex (cone of light) at 5 o'clock (right) or 7 o'clock (left)
• Malleus handle visible
• Pars tensa intact, pars flaccida normal

Abnormal findings:

Perforation:

• Central (pars tensa): Usually safe; history of otitis media
• Marginal/attic (pars flaccida): Risk of cholesteatoma ("unsafe ear")
• Size and location determine degree of hearing loss

Retraction pocket:

• Negative middle ear pressure (Eustachian tube dysfunction)
• Deep retraction with keratin debris → cholesteatoma

Effusion:

• Amber fluid level visible (otitis media with effusion)
• Reduced mobility on pneumatic otoscopy
• Bubbles visible if acute

Tympanosclerosis:

• White plaques (healed inflammation)
• No treatment needed unless ossicular fixation

Cholesteatoma:

• White mass in attic or posterior-superior quadrant
• Foul-smelling scanty discharge
• Requires urgent ENT referral

Schwartze sign (otosclerosis):

• Pink/red hue behind tympanic membrane (hypervascular promontory)
• Seen in active otosclerotic focus

Tuning Fork Tests (512 Hz)

Essential bedside assessment to differentiate conductive vs sensorineural hearing loss. Use 512 Hz fork (256 Hz too long decay; 1024 Hz inadequate bone conduction).

Rinne Test:

Technique:

1. Strike 512 Hz tuning fork
2. Place on mastoid process (bone conduction, BC)
3. When patient can no longer hear, immediately move to front of ear canal (air conduction, AC), prongs parallel to canal
4. Ask: "Can you still hear it?"

Interpretation:

• AC > BC (Rinne positive): Normal or sensorineural loss
• BC > AC (Rinne negative): Conductive loss
• False negative Rinne: Severe SNHL in test ear may cause BC to cross skull to contralateral (good) cochlea, falsely suggesting BC > AC

Weber Test:

Technique:

1. Strike 512 Hz tuning fork
2. Place on midline forehead or vertex
3. Ask: "Which ear is louder, or is it equal?"

Interpretation:

• Midline (no lateralization): Normal or symmetrical hearing loss
• Lateralizes to affected ear: Conductive loss (occlusion effect - bone-conducted sound "trapped" in affected ear)
• Lateralizes to normal ear: Sensorineural loss (diseased cochlea cannot perceive bone-conducted sound)

Combined Interpretation:

Whispered Voice Test

Sensitivity screening test for hearing impairment:

1. Stand 2 feet behind patient (prevent lip-reading)
2. Occlude non-test ear by tragal rubbing
3. Whisper 3 random numbers/letters
4. Positive if patient cannot repeat ≥3/6 characters
5. Sensitivity 90-100% for detecting greater than 30 dB hearing loss

Less reliable than audiometry but useful for screening, especially in primary care.

Additional Bedside Tests

Fistula Test:

• Apply tragal pressure or pneumatic otoscopy
• Positive if induces vertigo/nystagmus (abnormal communication between middle ear and labyrinth)
• Suggests cholesteatoma with lateral semicircular canal erosion, perilymph fistula, or superior semicircular canal dehiscence

Cranial Nerve Examination:

• CN VII (facial): Facial asymmetry, weakness (cholesteatoma, temporal bone malignancy, Ramsay Hunt)
• CN V (trigeminal): Facial numbness (cerebellopontine angle mass)
• CN VIII (vestibulocochlear): Already assessed via hearing and balance
• Other CNs: If cerebellopontine angle pathology suspected

---

6. Investigations

Audiometry

Pure Tone Audiometry (PTA):

Gold standard objective hearing assessment. Measures hearing threshold (softest sound detected 50% of time) across frequencies 250-8000 Hz.

Technique:

1. Air conduction (AC): Headphones/insert earphones deliver tones to external canal → entire auditory pathway tested
2. Bone conduction (BC): Vibrator on mastoid process transmits directly to cochlea, bypassing middle ear → isolated cochlear function assessment

Interpretation:

Normal hearing:

• AC and BC thresholds 0-20 dB HL across all frequencies
• No air-bone gap

Conductive hearing loss:

• AC thresholds reduced (greater than 20 dB HL)
• BC thresholds normal (0-20 dB HL)
• Air-bone gap ≥10 dB at ≥2 frequencies
• Gap size indicates degree of conductive component
• Maximum conductive loss ~60 dB (residual BC always present)

Sensorineural hearing loss:

• AC and BC thresholds equally reduced (both greater than 20 dB HL)
• No air-bone gap (AC = BC)
• Pattern indicates etiology:
  • "High-frequency sloping: Presbycusis, noise-induced"
  • "Low-frequency: Meniere's (early)"
  • "Flat: Sudden SNHL, ototoxicity"
  • "Cookie-bite (mid-frequency dip): Genetic SNHL"
  • "Notch at 4 kHz: Noise-induced (ear canal resonance frequency)"

Mixed hearing loss:

• AC thresholds reduced
• BC thresholds reduced but less than AC
• Air-bone gap present (AC worse than BC by ≥10 dB)
• BC below normal (sensorineural component)

Masking: Essential technique when testing asymmetric hearing loss. Noise presented to non-test ear prevents cross-hearing (sound crossing skull to better cochlea). Required when:

• AC difference ≥40 dB between ears
• BC testing if any AC asymmetry
• Air-bone gap present

Special Audiometric Findings:

Carhart notch (otosclerosis):

• Apparent BC dip at 2 kHz
• Artifact of stapes fixation reducing BC transmission
• Resolves after stapedectomy (confirms not true cochlear loss)

Noise notch:

• AC and BC dip at 4 kHz
• Noise-induced hearing loss hallmark
• May extend to 3-6 kHz with progression

Reverse slope:

• Low-frequency SNHL, high-frequency preservation
• Seen in: Meniere's, large vestibular aqueduct syndrome, genetic (WFS1 mutation)

Speech Audiometry

Speech Reception Threshold (SRT):

• Softest level patient can repeat 50% of spondee words (two-syllable words with equal stress, e.g., "baseball," "hotdog")
• Should correlate with pure tone average (PTA) ±6 dB
• Discrepancy suggests non-organic hearing loss or testing error

Speech Discrimination Score (SDS) / Word Recognition Score:

• Percentage of single-syllable words correctly repeated at comfortable loudness level
• Normal: ≥90% correct
• Reduced in SNHL: Reflects hair cell and neural dysfunction impairing clarity
• Normal in CHL: Cochlea intact; words clear if loud enough

Clinical significance:

• Poor SDS despite mild/moderate loss → retrocochlear pathology (vestibular schwannoma)
• SDS predicts hearing aid benefit (very poor SDS may require cochlear implant consideration)

Tympanometry (Impedance Audiometry)

Objective assessment of middle ear function independent of patient cooperation. Measures tympanic membrane compliance as ear canal pressure varied.

Technique:

• Sealed probe in ear canal
• Pressure varied from +200 to -400 daPa
• Tympanic membrane compliance plotted

Interpretation (Jerger Classification):

Clinical utility:

• Confirm otoscopic findings (effusion, perforation)
• Assess Eustachian tube function
• Detect ossicular pathology (otosclerosis vs discontinuity)
• Screening tool (especially pediatrics)

Acoustic Reflex Testing

Stapedius muscle contraction in response to loud sound (70-100 dB above threshold).

Absent acoustic reflexes suggest:

• Middle ear pathology (otosclerosis, ossicular fixation)
• Facial nerve pathology (stapedius innervation)
• Severe hearing loss (greater than 60 dB)
• Retrocochlear pathology (acoustic neuroma: reflex decay)

Reflex decay:

• Reflex amplitude decreases greater than 50% over 10 seconds despite continued stimulus
• Hallmark of retrocochlear pathology (vestibular schwannoma)

Otoacoustic Emissions (OAEs)

Sounds generated by outer hair cells in cochlea, recordable in ear canal. Requires:

• Intact outer hair cell function
• Patent middle ear (CHL abolishes OAEs)

Types:

• Transient-evoked (TEOAEs): Response to click stimulus
• Distortion-product (DPOAEs): Response to two simultaneous tones

Clinical applications:

• Newborn hearing screening
• Differentiate cochlear vs retrocochlear SNHL
• Auditory neuropathy spectrum disorder: OAEs present (hair cells intact) but ABR abnormal (neural dyssynchrony)
• Monitor ototoxicity during chemotherapy

Auditory Brainstem Response (ABR)

Electrophysiological test recording neural activity from cochlea to brainstem in response to click stimuli.

Five waveforms:

• Wave I: Distal CN VIII
• Wave II: Proximal CN VIII
• Wave III: Cochlear nucleus
• Wave IV: Superior olivary complex
• Wave V: Lateral lemniscus/inferior colliculus

Indications:

• Assess hearing in infants or adults unable to perform behavioral audiometry
• Differentiate cochlear vs retrocochlear SNHL
• Diagnose vestibular schwannoma: Prolonged wave I-V interpeak latency (greater than 4.4 ms) or interaural wave V latency difference (greater than 0.4 ms)
• Evaluate auditory neuropathy
• Intraoperative monitoring (posterior fossa surgery)

Limitations:

• Primarily assesses high-frequency (click 2-4 kHz) hearing
• Threshold estimation less accurate than behavioral audiometry
• Requires patient stillness (sedation often needed in children)

Imaging

MRI Internal Acoustic Meatus (IAM) with Gadolinium:

Gold standard for vestibular schwannoma detection.

Indications:

• Asymmetric SNHL (greater than 15 dB difference at ≥2 frequencies)
• Unilateral SNHL with normal contralateral ear
• Unilateral tinnitus
• Unexplained progressive unilateral hearing loss
• Abnormal ABR suggestive of retrocochlear pathology

Findings:

• Vestibular schwannoma: Enhancing mass in IAM or cerebellopontine angle
• Other pathology: Meningioma, arachnoid cyst, vascular loop compression

CT Temporal Bone:

Superior to MRI for bony anatomy.

Indications:

• Chronic otitis media / cholesteatoma: Assess ossicular erosion, mastoid disease, tegmen dehiscence, sigmoid sinus plate erosion
• Otosclerosis: Fenestral or retrofenestral lucency
• Temporal bone trauma: Fracture pattern (longitudinal vs transverse), ossicular injury
• Superior semicircular canal dehiscence syndrome: Bone dehiscence over superior canal
• Congenital anomalies: Mondini dysplasia, large vestibular aqueduct, ossicular malformation

Ultrasound, X-ray:

• Minimal role in adult hearing loss evaluation

Laboratory Testing

Limited role in routine hearing loss evaluation.

Consider in specific contexts:

Sudden SNHL:

• Full blood count (FBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP): Exclude infection/inflammation
• Autoimmune panel if bilateral/progressive: ANA, ANCA, RF, anti-cochlear antibodies (though sensitivity/specificity limited)
• Thyroid function tests (TFTs): Hypothyroidism association
• Syphilis serology (TPPA, RPR): Tertiary syphilis can cause SNHL

Fluctuating/progressive bilateral SNHL:

• Autoimmune panel: Granulomatosis with polyangiitis, SLE, Cogan syndrome
• Metabolic: Diabetes screening (HbA1c), lipid profile

Syndromic hearing loss:

• Genetic testing: Consider if family history, early-onset, syndromic features
• ECG: Long QT syndrome (Jervell and Lange-Nielsen)
• Urinalysis: Alport syndrome (hematuria + SNHL)

---

7. Diagnosis and Classification

Diagnostic Criteria

Hearing Loss Severity (WHO Grading):

Sudden Sensorineural Hearing Loss (SSNHL):

Diagnostic criteria: [11]

• ≥30 dB hearing loss
• Across ≥3 contiguous frequencies
• Occurring within ≤72 hours

Conductive Hearing Loss:

• Air-bone gap ≥10 dB at ≥2 frequencies on PTA
• Bone conduction thresholds normal (less than 20 dB HL)

Sensorineural Hearing Loss:

• Air conduction and bone conduction equally reduced (both greater than 20 dB HL)
• No air-bone gap (AC = BC)

Asymmetric Hearing Loss (requiring imaging):

• ≥15 dB difference between ears at ≥2 frequencies, OR
• ≥15 dB difference in speech discrimination score (SDS)

Differential Diagnosis

By Presentation Pattern:

Bilateral Gradual Hearing Loss:

Conductive:

• Chronic otitis media with effusion ("glue ear"
• uncommon in adults)
• Bilateral otosclerosis
• Paget's disease of temporal bone

Sensorineural:

• Presbycusis (most common)
• Noise-induced hearing loss
• Ototoxicity (aminoglycosides, cisplatin)
• Genetic SNHL (connexin 26 mutations)
• Metabolic (diabetes, hypothyroidism)
• Autoimmune (granulomatosis with polyangiitis, SLE, Cogan syndrome)

Unilateral or Asymmetric Hearing Loss:

Conductive:

• Chronic suppurative otitis media
• Cholesteatoma
• Otosclerosis (often asymmetric initially)
• Unilateral cerumen impaction

Sensorineural:

• Vestibular schwannoma (acoustic neuroma) - must exclude
• Meniere's disease (early stage unilateral; later bilateral in 30-50%)
• Viral labyrinthitis
• Temporal bone trauma/fracture
• Radiation-induced (nasopharyngeal carcinoma treatment)

Sudden Hearing Loss:

Conductive:

• Cerumen impaction (after irrigation attempt)
• Acute otitis media with effusion
• Barotrauma (hemotympanum, TM rupture, perilymph fistula)
• Traumatic ossicular discontinuity

Sensorineural:

• Idiopathic sudden SNHL (70-90% of cases) [11,12]
• Viral (HSV, VZV, CMV, mumps, measles)
• Vascular (labyrinthine artery occlusion, vertebrobasilar insufficiency)
• Autoimmune
• Perilymph fistula
• Meniere's disease (fluctuating)
• Vestibular schwannoma (rare presentation)
• Temporal bone fracture
• Ototoxicity (rapid onset with IV aminoglycosides)

Fluctuating Hearing Loss:

• Meniere's disease (classic triad: fluctuating SNHL, tinnitus, vertigo)
• Perilymph fistula
• Superior semicircular canal dehiscence syndrome
• Autoimmune inner ear disease

Progressive Unilateral Hearing Loss:

• Vestibular schwannoma (classic presentation)
• Chronic otitis media / cholesteatoma (conductive component)
• Meniere's disease (progressive SNHL develops)
• Temporal bone malignancy (rare)

Clinical Algorithms

Algorithm 1: Initial Assessment of Adult Hearing Loss

PATIENT REPORTS HEARING DIFFICULTY
           ↓
    HISTORY + EXAMINATION
    - Onset, laterality, progression
    - Associated symptoms (tinnitus, vertigo, otorrhoea)
    - Risk factors (noise, ototoxicity)
    - Otoscopy
    - Tuning forks (Rinne, Weber)
           ↓
    ┌──────┴──────┐
    ↓             ↓
CONDUCTIVE    SENSORINEURAL
(BC > AC)     (AC = BC, both ↓)
    ↓             ↓
Otoscopy      SUDDEN?
findings      ↓     ↓
    ↓        YES    NO
Wax? → Remove      ↓
Perforation?   EMERGENCY  Gradual
Effusion?          ↓       ↓
Cholesteatoma? Same-day   Audiometry
    ↓          ENT        ↓
Persistent     Oral       UNILATERAL?
CHL?           steroids   ↓     ↓
    ↓              ↓      YES   NO
ENT referral   MRI IAM    ↓     ↓
Audiometry         ↓      MRI   Audiometry
Consider       24-48hr    IAM   Management
surgery        follow-up  ↓     ↓
                   ↓      R/O   Hearing
               Audiometry Schwannoma aids
               Specialist     ↓     Treat
               follow-up  Consider cause
                          specialist

Algorithm 2: Sudden Sensorineural Hearing Loss Management [11,21,24]

SUDDEN HEARING LOSS (less than 72 hours)
           ↓
    OTOSCOPY + RINNE/WEBER
           ↓
    ┌──────┴──────┐
    ↓             ↓
CANAL CLEAR   WAX OCCLUSION
RINNE +ve         ↓
    ↓         REMOVE WAX
SSNHL             ↓
    ↓         Reassess
SAME DAY      If still HL →
ENT REFERRAL
    ↓
BASELINE PTA AUDIOMETRY
(Confirm ≥30 dB loss, ≥3 frequencies)
    ↓
ORAL PREDNISOLONE
1 mg/kg (max 60 mg) × 7-14 days
START IMMEDIATELY (within 72 hrs optimal)
    ↓
ARRANGE MRI IAM (within 4 weeks)
(exclude vestibular schwannoma)
    ↓
REPEAT AUDIOMETRY DAY 7-14
    ↓
┌───────┴────────┐
↓                ↓
RECOVERY      NO RECOVERY
Continue taper  Consider:
Follow-up      - Intratympanic steroids
               - Hyperbaric oxygen (if available, less than 2 weeks from onset)
               - Hearing rehabilitation

---

8. Management

General Principles

1. Treat reversible causes: Wax removal, infection management, surgical correction of CHL
2. Protect residual hearing: Noise protection, avoid ototoxins
3. Amplification for SNHL: Hearing aids (mild-severe), cochlear implants (severe-profound)
4. Address comorbidities: Cardiovascular risk factors, cognitive decline screening
5. Multidisciplinary approach: Audiologists, ENT surgeons, speech therapists, psychologists

Management of Conductive Hearing Loss

Cerumen Impaction:

First-line:

• Cerumenolytics: Sodium bicarbonate 5% ear drops, olive oil, commercial preparations (2-3 days pre-treatment softens wax)
• Microsuction: Gold standard; direct visualization, gentle, low perforation risk
• Irrigation: Effective but contraindicated if TM perforation, previous ear surgery, or acute infection; risk of perforation ~1:1000

Evidence:

• Microsuction preferred over irrigation (lower complication rate, better patient tolerance in studies)

Otitis Media with Effusion (OME):

Uncommon in adults; if present, investigate for underlying cause (nasopharyngeal carcinoma in high-risk populations, Eustachian tube obstruction).

Management:

• Treat underlying cause
• Watchful waiting (may resolve spontaneously)
• Grommet insertion if persistent and symptomatic (rare in adults)

Otosclerosis:

Non-surgical:

• Hearing aids: Effective for mild-moderate loss; avoids surgical risk
• Sodium fluoride (controversial; limited evidence for slowing progression)

Surgical:

• Stapedectomy / Stapedotomy: Remove fixed stapes, replace with prosthesis (piston)
• Success rate: 90-95% for closure of air-bone gap
• Risks: Sensorineural hearing loss (1-2%), facial nerve injury (less than 1%), dead ear (1%), vertigo, tinnitus
• Excellent long-term outcomes; improvement maintained in 85-90% at 10+ years [20]

Evidence:

• Cochrane review: Stapedotomy comparable outcomes to stapedectomy with potentially lower SNHL risk
• Hearing aids vs surgery: Patient choice; surgery offers potential "cure" but carries risks

Chronic Otitis Media / Cholesteatoma:

Medical:

• Topical antibiotics (ciprofloxacin ear drops) for active infection
• Aural toilet (microsuction to clear debris)

Surgical (definitive treatment):

• Tympanoplasty: Repair TM perforation
• Mastoidectomy: Remove cholesteatoma, diseased mastoid air cells
  • "Canal-wall-up (CWU): Preserves anatomy; higher recurrence risk"
  • "Canal-wall-down (CWD): Lower recurrence; requires lifelong ear care, no water exposure"
• Ossiculoplasty: Reconstruct ossicular chain if eroded

Bone-Anchored Hearing Aids (BAHA):

Indications:

• Conductive/mixed loss where conventional aids unsuitable:
  • Chronic otorrhoea (cannot wear in-ear device)
  • Congenital ear canal atresia
  • Single-sided deafness (transmits sound transcranially to good ear)

Mechanism:

• Titanium implant in mastoid bone
• Direct bone conduction vibration bypasses middle ear

Outcomes:

• Excellent sound quality for CHL
• High patient satisfaction (greater than 85%)
• Surgical complications: Skin reactions (10-20%), implant loss (5-10%)

Management of Sensorineural Hearing Loss

Hearing Aids:

Gold standard for mild-severe SNHL. Modern digital hearing aids provide frequency-specific amplification, noise reduction, directional microphones, and Bluetooth connectivity.

Types:

• Behind-the-ear (BTE): Most powerful; suitable for severe-profound loss
• Receiver-in-canal (RIC): Cosmetically appealing; good for high-frequency loss
• In-the-ear (ITE) / In-the-canal (ITC): Custom-molded; less visible
• Completely-in-canal (CIC): Nearly invisible; limited power

Fitting process:

1. Audiometric assessment (PTA, SDS)
2. Ear mold impressions (for custom devices)
3. Real ear measurement (verify prescribed amplification delivered)
4. Counseling and acclimatization period (brain requires weeks-months to adapt)
5. Follow-up adjustments

Outcomes:

• Improved speech understanding: 60-80% benefit in most patients
• Quality of life improvement quantified on Glasgow Hearing Aid Benefit Profile, APHAB
• Cognitive benefit: Hearing aid use associated with reduced dementia risk (HR 0.81) [2]
• Underutilization: Only 20-30% of eligible adults use hearing aids
  • "Barriers: Cost (£500-£3000 per aid privately; free on NHS UK), stigma, cosmetic concerns, inadequate counseling"

Evidence:

• RCTs demonstrate improved quality of life, reduced depression, improved cognitive function with hearing aid use
• Earlier intervention associated with better long-term outcomes

Cochlear Implants:

For severe-profound bilateral SNHL with inadequate hearing aid benefit.

Candidacy criteria:

• Severe-profound SNHL (threshold greater than 70 dB HL)
• Poor speech discrimination with optimally fitted hearing aids (less than 50% sentence recognition)
• No medical contraindications
• Realistic expectations, motivation to participate in rehabilitation

Mechanism:

• External speech processor captures sound
• Transmitter sends signal to internal receiver
• Electrode array in cochlea directly stimulates auditory nerve (bypasses non-functional hair cells)

Surgical procedure:

• Mastoidectomy, posterior tympanotomy
• Cochleostomy or round window insertion
• Electrode array threaded into scala tympani
• Receiver secured in mastoid bone

Outcomes (adults):

• Speech recognition: 60-80% sentence recognition in quiet (from less than 20% pre-op)
• Background noise remains challenging
• Quality of life improvement substantial
• Cost-effectiveness: QALY gain comparable to hip replacement
• Complications: Device failure (5% over 10 years), facial nerve injury (less than 1%), meningitis risk (pneumococcal vaccination required)

Evidence:

• Meta-analyses confirm superior speech outcomes vs hearing aids in severe-profound SNHL
• Bilateral cochlear implants superior to unilateral for speech in noise, sound localization [5]

Assistive Listening Devices:

Complement hearing aids:

• Induction loop systems: Hearing aids receive direct signal in public venues (theaters, churches)
• FM systems: Wireless transmission from speaker's microphone to hearing aid
• Captioning: Real-time text for lectures, meetings
• Alerting devices: Vibrating/flashing alarms (doorbell, phone, smoke detector)

Auditory Rehabilitation:

• Speechreading (lipreading) training: Improves comprehension, especially in noise
• Auditory training: Exercises to improve sound discrimination
• Communication strategies: Optimal positioning, environmental modification, conversation tactics
• Psychological support: Adjust to hearing loss, manage tinnitus

Management of Sudden Sensorineural Hearing Loss

Time-critical emergency. Prognosis directly correlates with treatment delay. [11,21,24,25]

Medical Management:

First-line: Oral Corticosteroids

• Regimen: Prednisolone 1 mg/kg (max 60 mg) daily × 7-14 days, then taper
• Mechanism: Reduce cochlear inflammation, stabilize blood-labyrinth barrier, improve microcirculation
• Evidence: Cochrane review shows benefit vs placebo (NNT ~5 for any recovery)
• Timing critical: Initiate within 72 hours optimal; benefit decreases after 2 weeks
• Contraindications: Uncontrolled diabetes, active peptic ulcer, severe hypertension (relative contraindications; risk-benefit assessment)

Salvage therapy: Intratympanic Corticosteroids

• Indication: Failed oral steroids, or oral steroids contraindicated
• Technique: Transtympanic injection of dexamethasone or methylprednisolone (4 injections over 2 weeks typical)
• Evidence: Meta-analysis shows benefit as salvage (42% improvement vs 25% in untreated) [21]
• Advantages: Avoid systemic side effects, higher cochlear concentration
• Disadvantages: Invasive, requires multiple visits, TM perforation (heals spontaneously)

Adjunctive therapies (limited/no evidence):

• Antivirals (acyclovir, valacyclovir): No proven benefit in RCTs; not routinely recommended
• Hyperbaric oxygen therapy (HBOT): Some evidence as adjunct if initiated within 2 weeks; limited availability [22,23]
• Vasodilators, anticoagulants, antioxidants: No RCT evidence; not recommended

Investigative Workup:

• MRI IAM with gadolinium: Mandatory to exclude vestibular schwannoma, demyelination, vascular malformation

  • Perform within 4 weeks (not urgent if already on steroids)
  • 1-3% of SSNHL cases have underlying schwannoma

• Laboratory tests (low yield but consider):

  • FBC, ESR, CRP (infection, vasculitis)
  • Autoimmune panel if bilateral or fluctuating
  • Syphilis serology if risk factors

Follow-up:

• Repeat audiometry: Day 7-14 to assess response
• Prognosis: [25]
  • ~33% complete recovery
  • ~33% partial recovery
  • ~33% no recovery
  • "Favorable factors: Young age, early treatment, absence of vertigo, mild-moderate loss"
  • "Poor prognosis: Severe-profound loss, vertigo, delayed treatment (greater than 2 weeks)"

Hearing Rehabilitation:

If no recovery:

• Hearing aid for residual hearing
• CROS (Contralateral Routing of Signal) hearing aid for single-sided deafness: Microphone on deaf ear transmits to hearing aid on good ear
• Bone-anchored hearing aid (BAHA) for single-sided deafness
• Cochlear implant if bilateral profound loss

Cardiovascular Risk Factor Management

Emerging evidence links cardiovascular disease to accelerated presbycusis. [6,10]

Modifiable risk factors:

• Smoking cessation: Associated with slower progression of hearing loss
• Blood pressure control: Hypertension linked to microvascular cochlear damage
• Glycemic control: Diabetes associated with 2× risk of hearing loss
• Lipid management: Dyslipidemia associated with hearing loss (mechanism unclear)

Recommendation: Optimize cardiovascular health as part of comprehensive hearing loss management, particularly in presbycusis.

Ototoxicity Prevention and Monitoring

For patients requiring ototoxic medications:

Aminoglycosides:

• Therapeutic drug monitoring (target trough less than 1 mg/L gentamicin)
• Baseline and serial audiometry (weekly during treatment, then 3 and 6 months post)
• Risk-benefit assessment: Use only when necessary
• Consider once-daily dosing (reduced toxicity vs multiple daily doses)

Platinum chemotherapy (cisplatin):

• Baseline audiometry
• Serial monitoring during treatment (before each cycle if high cumulative dose)
• Dose reduction or alternative agents if significant ototoxicity develops
• Sodium thiosulfate (cytoprotective agent): Reduces ototoxicity in pediatric cancer patients; emerging adult data

Loop diuretics:

• Generally reversible if dose reduced
• Synergistic toxicity with aminoglycosides: Avoid concurrent use if possible

Tinnitus Management

Accompanies 70-90% of SNHL cases. No cure, but management strategies reduce distress.

Approaches:

• Sound therapy: Background noise (white noise, nature sounds) reduces tinnitus perception
• Hearing aids: Amplification of ambient sound reduces tinnitus prominence
• Cognitive-behavioral therapy (CBT): Addresses maladaptive thoughts, reduces distress
• Tinnitus retraining therapy (TRT): Habituation through counseling + sound therapy
• Mindfulness-based interventions: Emerging evidence for efficacy

NOT recommended:

• Ginkgo biloba (no RCT evidence)
• Antidepressants/anticonvulsants (no effect on tinnitus; may help comorbid depression/anxiety)

Preventing Noise-Induced Hearing Loss

Public health priority, particularly for occupational and recreational noise exposure.

Occupational:

• Engineering controls: Soundproofing, equipment modification to reduce noise
• Personal protective equipment (PPE): Earplugs (30-40 dB attenuation), earmuffs (20-30 dB)
• Regulations: OSHA (US) mandates hearing conservation program if 8-hour TWA ≥85 dB
• Audiometric surveillance: Baseline and annual audiometry for exposed workers

Recreational:

• Personal audio devices: "60-60 rule" (≤60% volume for ≤60 minutes/day)
• Concerts, nightclubs: Wear earplugs (musician's earplugs attenuate evenly across frequencies)
• Firearms: Double protection (plugs + muffs) for shooting sports

Evidence:

• Consistent earplug use reduces noise-induced threshold shift by 10-30 dB
• Early intervention prevents irreversible hair cell loss

---

9. Prognosis and Outcomes

Natural History by Etiology

Presbycusis:

• Progressive: Average decline 1 dB/year in high frequencies after age 60
• Bilateral and symmetrical: Asymmetric loss suggests alternative etiology
• Irreversible: Hair cell loss permanent; progression can be slowed (CV risk reduction, noise protection) but not reversed
• Functional impact: Speech discrimination worsens disproportionately to pure tone loss (central auditory processing decline)
• Long-term: Most patients maintain serviceable hearing with aids through 80s-90s [6,10]

Noise-Induced Hearing Loss:

• Permanent threshold shift (PTS): Irreversible hair cell damage after sufficient cumulative exposure
• Progression: Stabilizes if noise exposure ceases; continues if exposure persists
• Pattern: High-frequency notch (4 kHz) initially; extends to 3-6 kHz, eventually affects speech frequencies (2-3 kHz)
• Prevention critical: No medical treatment once established

Sudden Sensorineural Hearing Loss:

Prognosis highly variable: [11,25]

• Complete recovery (threshold less than 25 dB): 32-65% (varies by study)
• Partial recovery: 25-40%
• No recovery: 20-30%

Favorable prognostic factors:

• Mild-moderate baseline loss (vs severe-profound)
• Early treatment initiation (less than 72 hours optimal; benefit up to 2 weeks)
• Younger age
• Absence of vertigo
• Upsloping audiometric pattern (low-frequency loss better prognosis than high-frequency)

Poor prognostic factors:

• Severe-profound loss (greater than 90 dB)
• Vertigo present
• Delayed treatment (greater than 2 weeks)
• Downsloping audiogram
• Elderly
• Diabetes

Spontaneous recovery: 32-70% experience some degree of spontaneous improvement (makes controlled trials challenging), but early steroids significantly improve outcomes.

Otosclerosis:

Natural history (untreated):

• Progressive CHL: Average 10 dB/decade
• Cochlear otosclerosis: 10-15% develop SNHL component (spongiotic bone affects cochlea)
• Bilateral: 70-80% (often asymmetric onset)

Surgical outcomes (stapedectomy):

• Success: 90-95% achieve air-bone gap closure less than 10 dB
• Durability: 85-90% maintain improvement at 10+ years
• Complications: SNHL (1-2%), dead ear (1%), revision surgery required (5-10%)
• Hearing aids alternative: Effective if surgery declined or contraindicated [20]

Chronic Otitis Media / Cholesteatoma:

Medical management alone (COM):

• Recurrent infections common
• Progressive conductive loss
• Risk of complications (mastoiditis, facial nerve palsy, meningitis)

Surgical outcomes:

• Tympanoplasty: 85-95% graft success (TM closure)
• Hearing improvement: Variable (depends on ossicular status; 60-80% improve)
• Cholesteatoma recurrence: CWU mastoidectomy 10-30%, CWD 5-10%
• Lifelong monitoring: Cholesteatoma can recur decades later

Long-Term Consequences of Untreated Hearing Loss

Cognitive Decline and Dementia:

Landmark evidence: Lancet Commission on Dementia Prevention (2020) identified hearing loss as the single largest modifiable risk factor for dementia, accounting for ~8% of dementia cases. [2]

Mechanisms:

• Social isolation: Reduced communication → cognitive disengagement
• Cognitive load: Effortful listening depletes executive function resources
• Sensory deprivation: Reduced auditory input → temporal lobe atrophy
• Common cause hypothesis: Shared vascular/neurodegenerative pathology

Epidemiological evidence:

• Mild hearing loss: HR 1.9 for dementia
• Moderate hearing loss: HR 3.0
• Severe hearing loss: HR 5.0 [2,4]

Intervention evidence:

• Hearing aid use: Associated with reduced dementia risk (HR 0.81)
• ACHIEVE trial (2023): RCT in progress assessing whether hearing intervention reduces cognitive decline

Mental Health:

• Depression: 2-3× higher prevalence in hearing loss vs normal hearing
• Anxiety: Social anxiety, generalized anxiety elevated
• Loneliness and social isolation: Communication barriers → withdrawal from social activities
• Quality of life: Reduced across physical, emotional, social domains

Safety and Falls:

• Falls risk: 3× higher in hearing loss (vestibular co-involvement, reduced spatial awareness, cognitive load)
• Mortality: Independently associated with increased all-cause mortality (HR 1.2-1.5)

Occupational and Economic Impact:

• Unemployment and underemployment: Higher rates in untreated hearing loss
• Earning potential: Reduced income (estimated 20-30% reduction in severe untreated hearing loss)
• Economic burden: Global cost $980 billion annually (healthcare, lost productivity, social costs)

Outcomes with Intervention

Hearing Aids:

Efficacy:

• Speech understanding: Improvement in greater than 80% of users
• Quality of life: Significant improvement on validated instruments (HHIA, APHAB)
• Cognitive benefit: Reduced dementia risk, improved cognitive performance on testing [2]
• Social engagement: Increased participation in social activities

Adherence:

• Underuse: 20-40% of hearing aid owners do not use regularly
• Predictors of success: Realistic expectations, adequate counseling, follow-up adjustments, mild-moderate loss (vs severe)

Cochlear Implants:

Adult outcomes:

• Speech recognition: Improvement from less than 20% pre-implant to 60-80% in quiet post-implant
• Noise: More challenging; 40-60% in background noise
• Quality of life: Substantial improvement
• Satisfaction: greater than 90% report satisfaction, would repeat decision
• Duration of deafness: Better outcomes if implanted earlier (shorter duration of auditory deprivation)

Long-term:

• Durability: Modern devices reliable; 95% device survival at 10 years
• Re-implantation: Device failure rare (less than 5% over 10 years); revision successful in greater than 95%

---

10. Complications

Complications of Untreated Hearing Loss

Otological:

• Chronic middle ear disease: Untreated COM → cholesteatoma, mastoiditis
• Vestibular dysfunction: Progressive balance impairment (presbycusis often includes vestibular degeneration)

Neurological:

• Cognitive decline and dementia (see above)
• Temporal lobe atrophy: Reduced auditory cortex volume on MRI in untreated SNHL
• Central auditory processing disorder: Progressive difficulty with speech in noise

Psychosocial:

• Depression and anxiety
• Social isolation and loneliness
• Reduced quality of life

Physical:

• Falls and injury: 3× increased risk
• Mortality: Increased all-cause mortality

Economic:

• Lost productivity: Unemployment, reduced earning potential
• Healthcare costs: Higher healthcare utilization

Complications of Hearing Loss Treatments

Hearing Aids:

Common (generally minor):

• Acoustic feedback (whistling): Poor fit, wax occlusion; adjust vent size or gain
• Discomfort: Ear mold too large/small; remake mold
• Occlusion effect: Own voice sounds "boomy"; vent ear mold or use open-fit device
• Earwax buildup: In-ear devices may worsen; regular cleaning

Rare:

• External otitis: From poorly cleaned ear mold
• Allergic reaction: To ear mold material (acrylic); use hypoallergenic materials

Stapedectomy/Stapedotomy (Otosclerosis Surgery):

Common:

• Taste disturbance (dysgeusia): 20-30% temporary (chorda tympani nerve manipulation); 5% permanent
• Tinnitus: 10-20% new or worsened (usually temporary)
• Vertigo: Transient in 30-50% (resolves days-weeks); persistent rare (1-2%)

Serious (rare):

• Sensorineural hearing loss: 1-2% (inner ear trauma during surgery)
• Dead ear (total hearing loss): less than 1% (labyrinthitis, perilymph gusher)
• Facial nerve injury: less than 1% (anatomic variation, nerve dehiscence)
• Persistent vertigo: 1-2% (perilymph fistula, granuloma)
• Revision surgery: 5-10% over 10 years (prosthesis displacement, refixation)

Cochlear Implantation:

Surgical complications:

• Facial nerve injury: less than 1% (transient paresis more common than permanent palsy)
• CSF leak (gusher): 1-2% (especially inner ear malformations); managed with packing, lumbar drain
• Device failure: less than 1% per year (cumulative 5% over 10 years); requires reimplantation
• Infection: Wound infection 2-5%; device removal rarely required
• Meningitis: Historical concern (cochlear implant recipients 30× baseline risk); mitigated by pneumococcal vaccination (now less than 0.1% risk)

Functional:

• Residual hearing loss: Insertion trauma destroys residual acoustic hearing (irrelevant if profound pre-op; hybrid devices preserve low-frequency hearing in selected cases)
• Vestibular dysfunction: 30-50% experience transient vertigo; long-term imbalance less than 10%
• Tinnitus: 10% new or worsened, 50% improved

Medical contraindications:

• MRI incompatibility: Older devices require magnet removal before MRI; newer devices MRI-compatible up to 1.5-3T
• Active middle ear infection: Defer until resolved
• Unrealistic expectations: Requires counseling

Intratympanic Corticosteroid Injection:

Common:

• Pain during injection: Local anesthetic (phenol or topical) reduces
• Temporary hearing loss: Fluid in middle ear for 24-48 hours (resolves)
• Vertigo: Transient (minutes-hours) from thermal effect or chemical labyrinthitis

Rare:

• Persistent TM perforation: 5-10% (most heal spontaneously; rare need for myringoplasty)
• Infection: less than 1% (otitis media)

---

11. Guidelines and Evidence

Key Clinical Guidelines

Evidence Base Summary

Presbycusis Pathophysiology: [6,8,9,10]

• Multicellular mechanisms: Hair cell loss, strial atrophy, neural degeneration, genetic susceptibility
• Cardiovascular risk factors accelerate progression
• Oxidative stress and inflammation central pathways

Hearing Loss and Dementia: [2,4]

• Robust epidemiological association (dose-response relationship)
• Hearing aid use associated with reduced risk (observational data)
• RCT (ACHIEVE trial) ongoing to establish causality

Sudden SNHL Management: [11,21,24,25]

• Oral corticosteroids superior to placebo (Cochrane review; NNT ~5)
• Intratympanic steroids effective as salvage (meta-analysis)
• Antivirals, anticoagulants, vasodilators: No RCT evidence; NOT recommended
• Hyperbaric oxygen: Limited evidence as adjunct if initiated early; not widely available

Stapedectomy Outcomes: [20]

• Success rate 90-95% (air-bone gap closure)
• Durable long-term (85-90% at 10+ years)
• Comparable to hearing aids for patient-reported outcomes; surgery offers potential "cure"

Cochlear Implants: [5]

• Superior to hearing aids for severe-profound SNHL (speech recognition, quality of life)
• Cost-effective (QALY comparable to hip replacement)
• Bilateral implants superior to unilateral for noise, localization

Landmark Studies and Trials

1. Lancet Commission on Dementia Prevention, Intervention, and Care (2020) [2]

• Identified 12 modifiable risk factors for dementia
• Hearing loss = largest single factor (~8% population attributable risk)
• Recommendation: Treat hearing loss to reduce dementia risk

2. Lin FR et al. Hearing Loss and Dementia Prevalence in Older Adults in the US. JAMA 2023 [2]

• Cross-sectional analysis of 2,413 older adults
• Dose-response relationship: Mild (HR 1.9), moderate (HR 3.0), severe (HR 5.0) hearing loss associated with dementia
• Hearing aid use associated with reduced risk (HR 0.81)

3. Chandrasekhar SS et al. Sudden Hearing Loss Guideline (AAO-HNS, 2019) [11]

• Systematic review and meta-analysis
• Strong recommendation: Oral corticosteroids
• Recommendation against: Antivirals, anticoagulants, vasodilators (insufficient evidence)

4. Plontke S et al. Intratympanic Corticosteroids for Sudden SNHL (Cochrane, 2022) [21]

• Meta-analysis of 30 RCTs
• Intratympanic steroids effective as salvage therapy after failed oral steroids
• Combination (oral + intratympanic) may offer modest additional benefit

5. Ying YM et al. Natural History of Untreated Idiopathic Sudden SNHL. Laryngoscope 2024 [25]

• Systematic review of spontaneous recovery rates
• 32-70% experience some spontaneous improvement
• Early treatment (oral steroids) significantly improves outcomes vs observation

6. Gates GA, Mills JH. Presbycusis. Lancet 2005 [6]

• Seminal review of age-related hearing loss
• Multifactorial etiology: Genetic, environmental, comorbidities
• High-frequency loss predominates; speech discrimination disproportionately affected

7. Molinier CE et al. Stapedotomy vs Hearing Aids in Otosclerosis (2022) [20]

• Prospective comparative study
• Stapedotomy: 90% success (air-bone gap closure)
• Hearing aids: Effective alternative
• Patient preference-driven choice

---

12. Special Populations

Hearing Loss in Older Adults (Geriatrics)

Prevalence:

• 40% of adults greater than 50 years
• 70% of adults greater than 70 years

Unique considerations:

Multimorbidity:

• Higher prevalence of cardiovascular disease, diabetes, cognitive impairment
• Polypharmacy: Ototoxic medication exposure (loop diuretics, aspirin)

Cognitive decline:

• Distinguish hearing loss from dementia (both cause communication difficulty)
• Hearing loss accelerates cognitive decline; intervention may slow [2,4]

Dexterity and vision:

• Manual dexterity limitations → difficulty manipulating small hearing aids, batteries
• Vision impairment → difficulty with hearing aid controls
• Solutions: Behind-the-ear devices (larger, easier), rechargeable batteries, caregiver training

Falls risk:

• Vestibular co-involvement common in presbycusis
• Hearing loss independently increases falls risk (3×)
• Comprehensive falls assessment indicated

Social isolation:

• Widowhood, retirement compound communication barriers
• Hearing loss intervention may reduce isolation

Management principles:

• Early hearing aid fitting (improves adaptation)
• Larger, easy-to-use devices
• Caregiver involvement in training
• Address comorbidities (CV risk, cognitive screening)
• Multidisciplinary approach (audiology, geriatrics, PT for falls)

Occupational Hearing Loss

Epidemiology:

• 16% of disabling adult hearing loss attributable to occupational noise
• High-risk industries: Construction, manufacturing, military, agriculture, entertainment

Noise exposure limits:

• OSHA (US): Permissible exposure limit (PEL) 90 dBA 8-hour TWA; hearing conservation program required at 85 dBA
• NIOSH (US): Recommended exposure limit (REL) 85 dBA 8-hour TWA
• EU: Exposure limit value 87 dBA; action level 80 dBA

Clinical features:

• Bilateral, symmetrical SNHL
• 4 kHz notch (ear canal resonance frequency)
• Progression with continued exposure

Prevention:

• Engineering controls: Noise reduction at source (primary prevention)
• PPE: Earplugs (30-40 dB attenuation), earmuffs (20-30 dB); double protection for greater than 100 dBA
• Audiometric surveillance: Baseline + annual audiometry
• Education: Hearing conservation programs

Medico-legal:

• Compensable condition in many jurisdictions
• Establish causation: Noise exposure history, characteristic audiometric pattern, latency
• Apportion contribution: Occupational vs non-occupational (aging, recreational noise)

Ototoxicity in Cancer Survivors

Prevalence:

• Cisplatin: 40-80% develop hearing loss (dose-dependent; greater than 300 mg/m² cumulative)
• Carboplatin: Lower risk (~10-15%)
• Radiation therapy: Temporal bone irradiation (nasopharyngeal cancer) causes progressive SNHL

Monitoring:

• Baseline audiometry before chemotherapy
• Serial audiometry during treatment (before each cycle if high-risk)
• Extended high-frequency audiometry (8-16 kHz) detects early ototoxicity

Management:

• Dose reduction if significant ototoxicity (balance oncologic efficacy vs quality of life)
• Sodium thiosulfate: Emerging evidence for otoprotection (especially pediatrics)
• Hearing aids if permanent threshold shift
• Counseling regarding long-term effects [5]

Single-Sided Deafness (SSD)

Etiologies:

• Sudden SNHL (30-40%)
• Vestibular schwannoma (20-30%)
• Meniere's disease (10-15%)
• Temporal bone trauma, surgery, congenital

Functional impact:

• Sound localization: Impossible with one ear (requires binaural hearing)
• Speech in noise: Significant difficulty (loss of binaural summation, head shadow effect)
• Safety: Reduced awareness of environmental sounds (traffic, alarms)

Management options:

CROS (Contralateral Routing of Signal) Hearing Aid:

• Microphone on deaf ear transmits wirelessly to hearing aid on good ear
• Overcomes head shadow effect
• Does NOT restore binaural hearing or localization
• Patient satisfaction variable (50-70% regular users)

Bone-Anchored Hearing Aid (BAHA):

• Implanted on deaf side; transmits sound transcranially to good ear
• Similar mechanism to CROS (no binaural restoration)
• Higher patient satisfaction than CROS (70-80%)

Cochlear Implant:

• Emerging indication for SSD (particularly if tinnitus prominent)
• Restores binaural hearing (unlike CROS/BAHA)
• Improved speech in noise, sound localization
• Tinnitus suppression in 60-80%
• Not universally funded; patient selection criteria evolving

---

13. Patient Education and Counseling

Communication Strategies for Patients with Hearing Loss

Environmental modifications:

• Reduce background noise: Turn off TV/radio during conversations; choose quiet restaurants
• Optimize lighting: Face speaker; lip-reading cues require good lighting
• Positioning: Sit in center of group (avoid ends of table); speaker 3-6 feet away

Communication tactics:

• Gain attention first: Tap shoulder, wave before speaking
• Face-to-face: Lip-reading provides 30-40% additional information
• Speak clearly, not loudly: Shouting distorts speech; clear articulation more helpful
• Rephrase, don't just repeat: If "fish" not understood, try "trout" instead of repeating "fish" louder
• Context clues: Provide topic context ("Let's talk about dinner plans") before details

For communication partners (family, caregivers):

• Patience and empathy: Frustration from repetition is mutual
• Avoid talking from another room: Visual cues impossible; wasted effort
• Check understanding: Ask "Did that make sense?" rather than assuming comprehension
• Advocate: Help patient navigate healthcare appointments (repeat instructions, clarify)

Hearing Aid Counseling

Realistic expectations:

• Hearing aids amplify sound but do not restore normal hearing
• Background noise remains challenging (even with advanced technology)
• Acclimatization period: Brain requires 4-12 weeks to adapt; initially overwhelming
• Gradual increase in wearing time (start 2-4 hours/day, build to all waking hours)

Maintenance and care:

• Daily cleaning (wipe with dry cloth; remove wax from receiver)
• Moisture control (desiccant jar overnight; avoid showering with aids)
• Battery replacement (weekly for disposables; nightly charging for rechargeable)
• Annual professional cleaning and maintenance

Common problems and solutions:

When to seek professional help:

• Persistent discomfort after 1 week
• Feedback despite wax removal
• Speech still unclear after 4 weeks acclimatization
• Hearing seems worse (may indicate progression; re-test)

Layperson Explanation: "Why Can I Hear But Not Understand?"

The Piano Analogy:

Imagine a piano where the high keys (right side) are broken. You can still hear music played on the piano—the low "boom" of the bass notes (left keys) is loud and clear. But the melody, played on the high keys, is missing.

Speech is like that piano:

• Vowels (a, e, i, o, u) are low-frequency sounds (bass notes). They give volume.
• Consonants (f, s, t, th, sh) are high-frequency sounds (high notes). They give clarity.

In hearing loss (especially age-related), the high-frequency "keys" are broken:

• You hear the volume (vowels) just fine.
• You miss the clarity (consonants).
• Example: "fish" sounds like "ish," "sit" sounds like "it."

That's why:

• People seem to be "mumbling" (you're missing consonants).
• Turning up the TV doesn't help (volume isn't the issue; clarity is).
• Noisy restaurants are impossible (background noise masks the already-weak consonants).

Hearing aids selectively turn up the "high keys" (consonants you're missing) without making the background noise deafening. It's not just a volume knob—it's smart amplification targeting what you've lost.

Dementia Prevention Messaging

"Protecting your hearing protects your brain."

Key messages for patients and families:

• Untreated hearing loss is the #1 modifiable risk factor for dementia
• Hearing loss forces your brain to work harder just to listen (effortful listening), which depletes resources needed for memory and thinking
• Social isolation from communication difficulty accelerates cognitive decline
• Hearing aids may reduce dementia risk by keeping your brain engaged

Action steps:

• Get hearing tested if you notice difficulty (don't wait "until it's bad enough")
• Use hearing aids consistently (all waking hours)
• Stay socially engaged (hearing aids enable participation)
• Manage cardiovascular risk factors (blood pressure, diabetes—good for heart AND ears)

---

14. Examination Focus: High-Yield Facts for Postgraduate Exams

MRCP / FRACP / MRCPCH

Key Associations:

Ototoxic Medications:

Tuning Fork Mastery (512 Hz):

False Negative Rinne:

• Patient with severe right SNHL may have BC > AC on right ear (appears conductive)
• Mechanism: Bone conduction crosses skull to good left ear, creating false impression BC > AC on right
• Weber lateralizes to left (good ear) → confirms right SNHL, not CHL

Audiometry Interpretation:

• Air-bone gap ≥10 dB = Conductive component
• No air-bone gap, both reduced = Sensorineural
• High-frequency sloping loss = Presbycusis, noise-induced
• Low-frequency loss = Meniere's (early), genetic (WFS1)
• Carhart notch (2 kHz BC dip) = Otosclerosis (artifact; resolves post-stapedectomy)
• 4 kHz notch = Noise-induced

Tympanometry:

• Type A: Normal
• Type As: Low compliance (otosclerosis, tympanosclerosis)
• Type Ad: High compliance (ossicular discontinuity)
• Type B: Flat (effusion, perforation, wax)
• Type C: Negative pressure (Eustachian tube dysfunction)

MRCS / FRCS (ENT) / FRACS (ORL-HNS)

Surgical Management:

Otosclerosis:

• Stapedectomy/stapedotomy: 90-95% success (air-bone gap closure)
• Risks: SNHL (1-2%), dead ear (1%), facial nerve injury (less than 1%), dysgeusia (20-30% temporary)
• Carhart notch disappears post-surgery (confirms artifact, not cochlear loss)

Cholesteatoma:

• Mastoidectomy: CWU (canal-wall-up) vs CWD (canal-wall-down)
  • "CWU: Preserves anatomy; higher recurrence (10-30%)"
  • "CWD: Lower recurrence (5-10%); requires lifelong ear care, no water exposure"
• Complications: Facial nerve palsy, sigmoid sinus thrombosis, meningitis, brain abscess, labyrinthine fistula

Cochlear Implantation:

• Candidacy: Severe-profound bilateral SNHL, less than 50% sentence recognition with hearing aids
• Outcomes: 60-80% sentence recognition in quiet (from less than 20% pre-op)
• Complications: Facial nerve injury (less than 1%), meningitis (less than 0.1% with pneumococcal vaccination), device failure (5% over 10 years)

Sudden SNHL Protocol:

• Immediate: Oral prednisolone 1 mg/kg × 7-14 days
• Salvage (if failed): Intratympanic dexamethasone (4 injections over 2 weeks)
• Mandatory: MRI IAM within 4 weeks (exclude vestibular schwannoma)
• Prognosis: 1/3 complete, 1/3 partial, 1/3 no recovery

Vestibular Schwannoma:

• Presentation: Progressive unilateral SNHL, tinnitus, imbalance
• Diagnosis: MRI IAM with gadolinium (gold standard)
• ABR: Prolonged wave I-V interpeak latency (greater than 4.4 ms), interaural wave V difference (greater than 0.4 ms)
• Management: Observation (slow-growing), stereotactic radiosurgery (Gamma Knife), microsurgical excision (translabyrinthine, retrosigmoid, middle fossa approaches)

MRCOG / FRANZCOG

Pregnancy and Hearing:

Otosclerosis:

• Often worsens during pregnancy (estrogen effects on bone remodeling)
• Counsel patients: May notice increased hearing loss; typically stabilizes postpartum
• Stapedectomy contraindicated during pregnancy (defer until after delivery)

Ototoxic Medications in Pregnancy:

• Aminoglycosides: Avoid if possible (fetal ototoxicity risk)
• Loop diuretics: Generally safe (reversible maternal ototoxicity)

Autoimmune Hearing Loss:

• Systemic lupus erythematosus, granulomatosis with polyangiitis can cause SNHL
• Flares during pregnancy possible
• Manage with rheumatology input

Common Viva Questions

1. "Describe the tuning fork tests and interpret this scenario: Rinne negative on the right, Weber lateralizes to the right."

Answer:

• Rinne test: 512 Hz fork on mastoid (BC), then in front of ear (AC). Normal: AC > BC (Rinne positive). Conductive loss: BC > AC (Rinne negative).
• Weber test: 512 Hz fork on midline forehead. Normal: Midline. CHL: Lateralizes to affected ear. SNHL: Lateralizes to good ear.
• Interpretation: Rinne negative right (BC > AC) + Weber right = Right conductive hearing loss.

2. "A patient presents with sudden deafness in one ear. What is your immediate management?"

Answer:

• History: Onset (less than 72 hours?), associated symptoms (vertigo, tinnitus), risk factors (ototoxins, trauma)
• Examination: Otoscopy (exclude wax, perforation), Rinne/Weber (confirm SNHL)
• Immediate management:
  • Oral prednisolone 1 mg/kg (max 60 mg) daily × 7-14 days (start within 72 hours)
  • "Audiology referral: PTA to confirm ≥30 dB loss across ≥3 frequencies"
  • "MRI IAM: Within 4 weeks (exclude vestibular schwannoma)"
• Prognosis: 1/3 complete recovery, 1/3 partial, 1/3 no recovery. Early treatment critical.

3. "What is the association between hearing loss and dementia?"

Answer:

• Lancet Commission (2020): Hearing loss is the largest modifiable risk factor for dementia (~8% population attributable risk)
• Dose-response: Mild hearing loss HR 1.9, moderate HR 3.0, severe HR 5.0 for dementia
• Mechanisms: Social isolation, cognitive load from effortful listening, sensory deprivation (auditory cortex atrophy)
• Intervention: Hearing aid use associated with reduced dementia risk (HR 0.81)
• Clinical implication: Screen for cognitive impairment in hearing loss; encourage hearing aid use for dementia prevention

4. "Describe the audiometric pattern in otosclerosis and explain Carhart's notch."

Answer:

• Otosclerosis audiometry: Conductive hearing loss (air-bone gap ≥10 dB), predominantly low frequencies
• Carhart notch: Apparent bone conduction dip at 2 kHz
• Mechanism: Artifact of stapes fixation reducing bone conduction transmission efficiency at 2 kHz (NOT true cochlear loss)
• Clinical significance: Notch disappears after stapedectomy, confirming it was artifact. Helps differentiate otosclerosis from mixed loss with true cochlear component.

5. "What are the candidacy criteria for cochlear implantation in adults?"

Answer:

• Audiological: Severe-profound bilateral SNHL (threshold greater than 70 dB HL); inadequate benefit from optimally fitted hearing aids (less than 50% sentence recognition)
• Medical: No contraindications (active middle ear infection, cochlear aplasia on imaging)
• Psychological: Realistic expectations, motivation for rehabilitation
• Social: Support system for post-operative auditory training
• Outcomes: 60-80% sentence recognition in quiet (from less than 20% pre-op); quality of life improvement substantial

---

15. Related Topics and Cross-References

Prerequisites (understand first):

• Anatomy of the Ear (ent-ear-anatomy): External, middle, inner ear structures; auditory pathway
• Auditory Physiology (physio-hearing): Mechanism of sound transduction; tonotopic organization; auditory nerve encoding

Differential Diagnoses (consider concurrently):

• Vestibular Schwannoma (ent-acoustic-neuroma): Unilateral progressive SNHL + tinnitus + imbalance
• Meniere's Disease (ent-menieres): Fluctuating SNHL + episodic vertigo + tinnitus + aural fullness
• Otosclerosis (ent-otosclerosis): Progressive CHL, young women, family history, Carhart notch
• Chronic Otitis Media (ent-otitis-media-chronic): Conductive loss, otorrhoea, TM perforation/retraction
• Cholesteatoma (ent-cholesteatoma): "Unsafe ear," foul otorrhoea, conductive loss, erosive complications

Consequences (sequelae to monitor):

• Cognitive Decline and Dementia (neuro-dementia-risk-factors): Hearing loss = largest modifiable risk factor
• Depression and Anxiety (psych-depression-elderly): 2-3× prevalence in hearing loss
• Falls in Older Adults (geriatrics-falls): 3× risk with hearing loss (vestibular co-involvement)
• Tinnitus (ent-tinnitus): Accompanies 70-90% of SNHL; management strategies

Related Conditions:

• Ototoxicity (pharmacology-ototoxic-drugs): Aminoglycosides, platinum chemotherapy, loop diuretics, salicylates
• Noise-Induced Hearing Loss (occupational-medicine-noise): Prevention, surveillance, compensation
• Temporal Bone Trauma (ent-temporal-bone-fracture): Longitudinal vs transverse; hearing and facial nerve outcomes
• Autoimmune Inner Ear Disease (rheumatology-autoimmune-hearing): Rapidly progressive bilateral SNHL; steroid-responsive

Investigations:

• Audiometry Interpretation (ent-audiometry): PTA, speech audiometry, tympanometry, OAE, ABR
• MRI Internal Acoustic Meatus (radiology-mri-iam): Vestibular schwannoma detection; protocol and interpretation

Management:

• Hearing Aids (ent-hearing-aids): Types, fitting process, troubleshooting, outcomes
• Cochlear Implants (ent-cochlear-implants): Candidacy, surgical technique, programming, rehabilitation
• Stapedectomy (ent-stapedectomy): Indications, technique, outcomes, complications

---

16. Summary: Key Take-Home Points

1. Hearing loss affects 1 in 6 adults, increasing to 70% of adults greater than 70 years. Presbycusis (age-related SNHL) is the most common cause.

2. Classify by type: Conductive (BC > AC, pathology external/middle ear) vs Sensorineural (AC = BC both reduced, pathology cochlea/nerve) using tuning forks and audiometry.

3. Sudden SNHL is an emergency: ≥30 dB loss across ≥3 frequencies within 72 hours. Immediate oral prednisolone 1 mg/kg within 72 hours improves outcomes. MRI IAM mandatory to exclude vestibular schwannoma.

4. Unilateral or asymmetric SNHL requires MRI IAM to exclude vestibular schwannoma (3% of cases).

5. Hearing loss is the largest modifiable dementia risk factor (Lancet Commission): Mild HL (HR 1.9), moderate (HR 3.0), severe (HR 5.0). Hearing aid use reduces risk (HR 0.81).

6. Otosclerosis: Progressive CHL in young women, often worsens with pregnancy. Carhart notch (BC dip at 2 kHz) is artifact of stapes fixation, resolves post-stapedectomy (90-95% success rate).

7. Noise-induced hearing loss: Characteristic 4 kHz notch on audiometry (ear canal resonance frequency). Prevention critical (earplugs, earmuffs, engineering controls); irreversible once established.

8. Audiometry interpretation:

   • Air-bone gap ≥10 dB = Conductive component
   • No gap, both reduced = Sensorineural
   • High-frequency sloping = Presbycusis, noise-induced
   • Low-frequency = Meniere's (early)

9. Hearing aids: Gold standard for mild-severe SNHL. Improve speech understanding, quality of life, and may reduce dementia risk. Underutilized: Only 20-30% of eligible adults use them.

10. Cochlear implants: For severe-profound bilateral SNHL with less than 50% sentence recognition with hearing aids. Improve speech understanding from less than 20% to 60-80% in quiet.

11. Ototoxicity monitoring: Aminoglycosides (irreversible SNHL), cisplatin (dose-dependent greater than 300 mg/m²), loop diuretics (reversible unless with aminoglycosides). Serial audiometry essential.

12. Cholesteatoma ("unsafe ear"): Foul-smelling scanty otorrhoea, white mass on otoscopy, erosive complications (mastoiditis, facial palsy, intracranial). Urgent ENT referral for surgical management.

13. Tuning fork tests (512 Hz):

    • Rinne: AC > BC (normal/SNHL), BC > AC (CHL)
    • Weber: Midline (normal/symmetrical), lateralizes to affected ear (CHL), lateralizes to good ear (SNHL)

14. Tympanometry types: A (normal), As (otosclerosis), Ad (ossicular discontinuity), B (effusion/perforation), C (Eustachian tube dysfunction)

15. Presbycusis clinical pearl: High frequencies lost first → consonants (f, s, t, th) affected → patients hear volume (vowels) but miss clarity (consonants) → "I can hear but can't understand"

---

References

1. Campello CP, Lemos SM, Andrade KC, et al. Migraine associated with tinnitus and hearing loss in adults: a systematic review. Int J Audiol. 2024;63(1):1-7. PMID: 36459425

2. Huang AR, Jiang K, Lin FR, et al. Hearing Loss and Dementia Prevalence in Older Adults in the US. JAMA. 2023;329(2):171-173. PMID: 36625819

3. Yuan Y, Guo W, Tang J, et al. Molecular epidemiology and functional assessment of novel allelic variants of SLC26A4 in non-syndromic hearing loss patients with enlarged vestibular aqueduct in China. PLoS One. 2012;7(11):e49984. PMID: 23185506

4. Zhao F, Chen Y, Song Y, et al. Hearing loss and cognitive impairment among older adults: findings from the China health and retirement longitudinal study. BMC Public Health. 2025;25(1):1588. PMID: 40307727

5. Bass JK, Wang M, Thaxton RL, et al. Association of hearing loss with patient-reported functional outcomes in adult survivors of childhood cancer. J Natl Cancer Inst. 2024;116(4):596-605. PMID: 38048603

6. Gates GA, Mills JH. Presbycusis. Lancet. 2005;366(9491):1111-1120. PMID: 16182900

7. Gates GA, Caspary DM, Clark K, et al. Presbycusis. Otolaryngol Head Neck Surg. 1989;100(4):266-271. PMID: 2498811

8. Keithley EM. Pathology and mechanisms of cochlear aging. J Neurosci Res. 2020;98(9):1674-1684. PMID: 31066107

9. Zhao J, Shen Y, Cao L, et al. Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy. Adv Sci (Weinh). 2025;12(3):e2410413. PMID: 40349177

10. Tawfik KO, Klepper K, Saliba J, et al. Advances in understanding of presbycusis. J Neurosci Res. 2020;98(9):1685-1697. PMID: 30950547

11. Kuhn M, Heman-Ackah SE, Shaikh JA, et al. Sudden sensorineural hearing loss: a review of diagnosis, treatment, and prognosis. Trends Amplif. 2011;15(3):91-105. PMID: 21606048

12. Young YH. Contemporary review of the causes and differential diagnosis of sudden sensorineural hearing loss. Int J Audiol. 2020;59(4):243-253. PMID: 31714154

13. Al-Azzawi M, Stapleton E. Blood tests as biomarkers for the diagnosis and prognosis of sudden sensorineural hearing loss in adults: a systematic review. J Laryngol Otol. 2023;137(9):977-984. PMID: 36794400

14. Epstein S, Reilly JS. Sensorineural hearing loss. Pediatr Clin North Am. 1989;36(6):1501-1520. PMID: 2685727

15. Shearer AE. Genetic testing for pediatric sensorineural hearing loss in the era of gene therapy. Curr Opin Otolaryngol Head Neck Surg. 2024;32(5):352-356. PMID: 39146193

16. Dougherty W, Kesser BW. Management of Conductive Hearing Loss in Children. Otolaryngol Clin North Am. 2015;48(6):955-974. PMID: 26360369

17. Bergstrom L. Continuing management of conductive hearing loss during language development. Int J Pediatr Otorhinolaryngol. 1980;2(1):3-9. PMID: 6765127

18. Raz Y, Lustig LR. Surgical management of conductive hearing loss in children. Otolaryngol Clin North Am. 2002;35(4):853-875. PMID: 12487086

19. Stewart E, Gallagher E, Leyden J. Diagnosis and management of conductive hearing loss in children with trisomy 21. J Paediatr Child Health. 2018;54(11):1242-1245. PMID: 29790248

20. Molinier CE, Gallois Y, Deguine O, et al. Stapedotomy Versus Hearing Aids in the Management of Conductive Hearing Loss Caused by Otosclerosis: A Prospective Comparative Study. Otol Neurotol. 2022;43(7):773-780. PMID: 35878633

21. Plontke SK, Meisner C, Agrawal S, et al. Intratympanic corticosteroids for sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2022;7(7):CD008080. PMID: 35867413

22. LeGros V, Murphy-Lavoie HM. HBO2 for sudden sensorineural hearing loss. Undersea Hyperb Med. 2020;47(2):271-295. PMID: 32574445

23. Moghib HA, Dawoud MM, Altalab AA, et al. Evaluating hyperbaric oxygen therapy as an adjunct to corticosteroids in sudden sensorineural hearing loss: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2025;282(10):4949-4966. PMID: 40405024

24. Balai E, Gupta A, Darr A, et al. Comparing the use of high dose to standard dose corticosteroids for the treatment of sudden sensorineural hearing loss in adults - A systematic review. Auris Nasus Larynx. 2024;51(1):11-24. PMID: 37127508

25. Ying YM, Tseng CC, Shin JJ, et al. Natural History of Untreated Idiopathic Sudden Sensorineural Hearing Loss. Laryngoscope. 2024;134 Suppl 9:S1-S15. PMID: 38808803

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient management.